HER3-DXd for Advanced Breast Cancer After T-DXd
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug called HER3-DXd (alone or combined with other medicines) for people with advanced breast cancer that has already been treated with T-DXd (Enhertu) and then got worse. The goal is to see if the new drug can shrink tumors safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have already been treated with T-DXd (Enhertu) and your cancer got worse while on it or within 2 months after stopping.
- Your tumor is HER2-positive or HER2-low (tested by your doctor).
- You are willing to have a small needle sample (biopsy) taken from a tumor before, during, and after the study.
- You have at least one tumor that can be seen on a CT or MRI scan.
- Your general health is good enough to be up and about (ECOG 0 or 1), and you are 18 or older.
- You agree to use highly effective birth control (if applicable) and to not donate eggs or sperm during and for several months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for advanced breast cancer that is HR-positive, HER2-low or ultralow, and a non-luminal subtype. It tests if a targeted antibody-drug conjugate (T-DXd) works better than the usual first-line therapy combining a CDK4/6 inhibitor with hormone therapy. This study is for people who have not had any treatment for advanced disease.
This trial tests a drug called T-DXd (a targeted chemotherapy) combined with hormone therapy for people with HER2-positive and hormone receptor-positive advanced breast cancer who have not had prior treatment for their metastatic disease. It includes an upfront phase, a maintenance phase, and a retreatment phase to see if restarting T-DXd is effective.
This Phase 2 trial tests patritumab deruxtecan (U3-1402) in people with HER2-negative, hormone-receptor positive (HR+) breast cancer that cannot be removed by surgery or has spread. It’s for cancers that have progressed despite endocrine therapy plus a CDK4/6 inhibitor, aiming to shrink tumors and control the disease.
This trial tests a targeted therapy called Trastuzumab Deruxtecan (T-DXd) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those who have not yet received any chemotherapy or HER2-targeted treatment for metastatic disease. The study also focuses on managing side effects early, using digital tools to track symptoms.
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
This trial is studying a drug called T-DXd (trastuzumab deruxtecan) for Chinese women with advanced breast cancer that has a certain protein (HER2) either in high or low amounts. It aims to see how well the drug works in real-world settings.
Hear when a new HER2-positive Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.